Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells

Radiotherapy and Oncology

Volumn 92, Issue 3, 2009, Pages 345-352

  Xing, Ligang ^a,b   Sun, Xiaorong ^a,b   Deng, Xuelong ^a   Kotedia, Khushali ^a   Urano, Muneyasu ^a   Koutcher, Jason A ^a   Ling, C Clifton ^a   Li, Gloria C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

5 Fluorocytosine; Bystander effect; Cytosine deaminase; Radiosensitization; Uracil phosphoribosyltransferase

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG METABOLISM; FLUORINE NUCLEAR MAGNETIC RESONANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BYSTANDER EFFECT; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; FLUCYTOSINE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, NUDE; PENTOSYLTRANSFERASES; PROBABILITY; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; REFERENCE VALUES; TRANSFECTION;

EID: 69949133460     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.04.003     Document Type: Article

References (23)

1. Greco O., and Dachs G.U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 187 (2001) 22-36
2. Daher G.C., Harris B.E., and Diasio R.B. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48 (1990) 189-222
3. Hwang H.S., Davis T.W., Houghton J.A., and Kinsella T.J. Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization. Cancer Res 60 (2000) 92-100
4. Anello R., Cohen S., Atkinson G., and Hall S.J. Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation. J Urol 164 (2000) 2173-2177
5. Kievit E., Nyati M.K., Ng E., et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 60 (2000) 6649-6655
6. Trinh Q.T., Austin E.A., Murray D.M., Knick V.C., and Huber B.E. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55 (1995) 4808-4812
7. Kanai F., Kawakami T., Hamada H., et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 58 (1998) 1946-1951
8. Tiraby M., Cazaux C., Baron M., Drocourt D., Reynes J.P., and Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 167 (1998) 41-49
9. Erbs P., Regulier E., Kintz J., et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 60 (2000) 3813-3822
10. Teicher B.A., Lazo J.S., and Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41 (1981) 73-81
11. Sasabe E., Zhou X., Li D., Oku N., Yamamoto T., and Osaki T. The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 120 (2007) 268-277
12. Xing L., Deng X., Kotedia K., et al. Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein. Acta Oncol (Stockholm, Sweden) 47 (2008) 1211-1220
13. Adelstein D.J., Saxton J.P., Lavertu P., et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 19 (1997) 567-575
14. Smith T.J., Ryan L.M., Douglass Jr. H.O., et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 42 (1998) 269-276
15. Kievit E., Bershad E., Ng E., et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 59 (1999) 1417-1421
16. Freytag S.O., Movsas B., Aref I., et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15 (2007) 1016-1023
17. Corban-Wilhelm H., Ehemann V., Becker G., Greulich D., Braun K., and Debus J. Comparison of different methods to assess the cytotoxic effects of cytosine deaminase and thymidine kinase gene therapy. Cancer Gene Ther 11 (2004) 208-214
18. Khil M.S., Kim J.H., Mullen C.A., Kim S.H., and Freytag S.O. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res 2 (1996) 53-57
19. Huber B.E., Austin E.A., Richards C.A., Davis S.T., and Good S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91 (1994) 8302-8306
20. 19F-NMR spectroscopy. Gene Ther 9 (2002) 1564-1575
21. Kambara H., Tamiya T., Ono Y., et al. Combined radiation and gene therapy for brain tumors with adenovirus-mediated transfer of cytosine deaminase and uracil phosphoribosyltransferase genes. Cancer Gene Ther 9 (2002) 840-845
22. 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 10 (2004) 916-928
23. Gade T.P., Koutcher J.A., Spees W.M., et al. Imaging transgene activity in vivo. Cancer Res 68 (2008) 2878-2884